BioSpace News Archive

Clinical partnership of phase 1/1b combination clinical trial with Genome & Company’s GEN-001, microbiome-based immuno-oncology therapy, and avelumab (BAVENCIO®), Merck KGaA, Darmstadt, Germany and Pfizer Inc.'s anti-PD-L1 antibody in oncology indications

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced that it has received a favorable Letter of Advice from the US Food and Drug Administration for QIXLEEF.

Tauriga Sciences, Inc. announced that it has amended, in relevant part, the certificate of incorporation of Tauriga Business Development Corp., a wholly owned Delaware incorporated subsidiary of the Company, to change this subsidiary’s name to Tauriga Pharma Corp., verified as complete by the Delaware Secretary of State’s office on January 7, 2020.

ContraFect Corporation announced that it has extended early access to exebacase to individual named patients with chronic post-operative prosthetic joint infections under Temporary Authorizations for Use from the French National Agency for Medicines and Health Products Safety in collaboration with Dr. Tristan Ferry at the Hôpital de la Croix Rousse in Lyon, France.

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced the closing of a private placement financing (the “Offering”) resulting in gross proceeds of approximately $6.9 million from certain accredited investors

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2019 financial results on Friday, February 7, 2020 before the market opens.

Spectra Medical Devices - Huons Co., Ltd. are proud to announce the FDA approval of their Abbreviated New Drug Application (ANDA) for Bupivacaine HCl with Dextrose USP, 0.75% / 8.25% in 2 mL ampules.

Today, 3D Systems (NYSE: DDD) and CollPlant Biotechnologies (NASDAQ: CLGN), announced signing a joint development agreement intended to play a pivotal role in advancing and accelerating breakthroughs in the biomedical industry.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced a regulatory update following the completion of a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, regarding its two pivotal studies, MORE and CHOICES.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today is providing a corporate update that will be presented at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 8:30 a.m. PST